For forty-six years, the San Antonio Breast Cancer Symposium’s mission has been to provide state-of-the-art information on breast cancer research. The University of Kansas Cancer Center Breast Cancer Year in Review is a condensed review of the SABCS meeting held in December and it gives healthcare providers the opportunity to learn about the latest advances in oncology education and translate science into better patient care. This accredited meeting is hosted as an in-person conference only with on-demand access for registered attendees.
Meeting registrations will require a credit card as a cancellation hold. A fee of $125 will only be incurred in the event of a no-show or cancellation within 14 days without written confirmation to the Total Health Program Team.
Accreditation Information | 4.00
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 4.00 ANCC contact hours.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 4.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 4.00 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Determine best application of new targeted therapies in patients with early stage and metastatic disease
Discuss the advances in systemic therapy likely to change current practices for treatment of breast cancer
Know how to utilize genomic tools for systemic therapy decision making and prediction of treatment response.
Be familiar with germ-line genetic testing options for hereditary breast cancer, including advantages and disadvantages of extended panel testing
Evaluate local therapy options for operable breast cancer depending on stage, and the use of neoadjuvant therapy
Identify evidence-based recommendations for decreasing symptoms and improving quantity and/or quality of life in survivors
What to Expect
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Enduring video content for watching at your leisure
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources
Catered meals through-out the program